A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.

Because COVID-19 is caused by a virus, antibiotics cannot be used to treat it. However, Pulia says physicians may feel they are erring on the safe side by assuming the patient could also have ...

On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.